TSG Advice Partners LLC Purchases New Stake in Merck & Co., Inc. $MRK

TSG Advice Partners LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,054 shares of the company’s stock, valued at approximately $734,000.

Other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its position in Merck & Co., Inc. by 23.8% in the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after acquiring an additional 2,969,856 shares during the last quarter. Bank of America Corp DE increased its position in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Merck & Co., Inc. by 263.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock valued at $347,334,000 after purchasing an additional 1,959,778 shares during the last quarter. Wellington Management Group LLP lifted its stake in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Merck & Co., Inc. in the 3rd quarter valued at approximately $260,560,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck plans to present new data from its oral HIV portfolio at HIV Glasgow 2026, including Phase 3 analyses and patient-reported outcomes for the once-weekly investigational ISL/LEN regimen. The FDA has also accepted supplemental applications for IDVYNSO, with a decision expected in 2027. Merck HIV portfolio data
• Positive Sentiment: Merck’s personalized melanoma-vaccine strategy is drawing investor attention because a successful approach could reduce recurrence and support long-term oncology growth. Merck personalized cancer strategy
• Positive Sentiment: Merck posted third-quarter revenue of $18.09 billion, up 4.7% year over year and ahead of expectations, while adjusted earnings of $2.49 per share exceeded consensus by approximately 19%. Merck third-quarter review
• Neutral Sentiment: Cantor Fitzgerald raised its MRK price target from $145 to $155 but kept a Neutral rating, indicating limited conviction at current valuation levels. Cantor Fitzgerald Merck target
• Neutral Sentiment: Another analyst raised Merck’s price target to $171, while broader reports highlight potential opportunities in biotechnology reagents and RNA-targeting drug discovery, areas where Merck is an industry participant. Merck price target raised to $171
• Negative Sentiment: Freedom Broker increased its target from $125 to $140 but maintained a Hold rating; the new target remains below the stock’s reported trading level, signaling downside concerns. Freedom Broker Merck target

Merck & Co., Inc. Trading Down 0.6%

Shares of NYSE MRK opened at $148.58 on Tuesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The firm has a 50 day moving average price of $146.82 and a two-hundred day moving average price of $126.89. The stock has a market cap of $366.58 billion, a P/E ratio of 153.18, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. The firm had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.58 earnings per share. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRK. Jefferies Financial Group boosted their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Citigroup upped their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Scotiabank upped their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a report on Tuesday, September 29th. HSBC increased their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Wells Fargo & Company lifted their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Seventeen investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $155.85.

Insiders Place Their Bets

In related news, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This trade represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. 0.17% of the stock is currently owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.